J. P. Kinsella, A. Greenough, and S. H. Abman, Bronchopulmonary dysplasia, Lancet, vol.367, pp.1421-1431, 2006.

L. Egreteau, J. Y. Pauchard, D. S. Semama, J. Matis, A. Liska et al., Chronic oxygen dependency in infants born at less than 32 weeks' gestation: incidence and risk factors, Pediatrics, vol.108, p.26, 2001.

A. T. Shennan, M. S. Dunn, A. Ohlsson, K. Lennox, and E. M. Hoskins, Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period, Pediatrics, vol.82, pp.527-532, 1988.

V. Bhandari, Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia, Birt Defects Res A Clin Mol Teratol, vol.100, pp.189-201, 2014.

H. L. Halliday, Postnatal steroids: a dilemma for the neonatologist, Acta Paediatr Oslo Nor, vol.90, pp.116-118, 1992.

B. A. Yoder, M. Harrison, and R. H. Clark, Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants, Pediatrics, vol.124, pp.673-679, 2009.

C. Romagnoli, E. Zecca, G. Vento, D. Carolis, M. P. Papacci et al., Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants, Intensive Care Med, vol.25, pp.717-721, 1999.

L. W. Doyle, R. A. Ehrenkranz, and H. L. Halliday, Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants, Cochrane Database Syst Rev, vol.5, p.1146, 2014.

L. W. Doyle, R. A. Ehrenkranz, and H. L. Halliday, Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants, Cochrane Database Syst Rev, vol.5, p.1145, 2014.

L. W. Doyle, R. A. Ehrenkranz, and H. L. Halliday, Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.217-224, 2010.

L. W. Doyle, R. A. Ehrenkranz, and H. L. Halliday, Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.289-296, 2010.

L. W. Doyle, R. A. Ehrenkranz, and H. L. Halliday, Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review, Neonatology, vol.98, pp.111-117, 2010.

O. Baud, L. Maury, F. Lebail, D. Ramful, E. Moussawi et al., Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial, Lancet Lond Engl, vol.387, pp.1827-1836, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01278609

O. Baud, L. Foix-l&apos;helias, M. Kaminski, F. Audibert, P. H. Jarreau et al., Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants, N Engl J Med, vol.341, pp.1190-1196, 1999.

, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants, Pediatrics, vol.109, pp.330-338, 2002.

A. L. Jefferies, Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health, vol.17, pp.573-574, 2012.

M. C. Walsh, Q. Yao, J. D. Horbar, J. H. Carpenter, S. K. Lee et al., Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks, PEDIATRICS, vol.118, pp.1328-1335, 2006.

E. S. Shinwell, L. Lerner-geva, A. Lusky, and B. Reichman, Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants, Arch Dis Child Fetal Neonatal Ed, vol.92, pp.30-33, 2007.

L. Gortner, B. Misselwitz, D. Milligan, J. Zeitlin, L. Kollée et al., Rates of Bronchopulmonary Dysplasia in Very Preterm Neonates in Europe: Results from the MOSAIC Cohort, Neonatology, vol.99, pp.112-117, 2011.

P. Ancel, F. Goffinet, . Epipage-2-writing, and . Group, Survival and morbidity of preterm children born at 22 through 34 weeks' gestation in france in 2011: Results of the epipage-2 cohort study, JAMA Pediatr, 2015.

J. Zeitlin, M. El-ayoubi, P. Jarreau, E. S. Draper, B. Blondel et al., Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort, J Pediatr, vol.157, pp.733-739, 2010.

D. G. Sweet, V. Carnielli, G. Greisen, M. Hallman, E. Ozek et al., European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update, Neonatology, vol.97, pp.402-417, 2010.

H. L. Halliday, R. A. Ehrenkranz, and L. W. Doyle, Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants, Cochrane Database Syst Rev, p.1146, 2010.

D. G. Sweet, V. Carnielli, G. Greisen, M. Hallman, E. Ozek et al., European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2013 update, Neonatology, vol.103, pp.353-368, 2013.

D. L. Sackett, W. Rosenberg, J. Gray, R. B. Haynes, and W. S. Richardson, Evidence based medicine: what it is and what it isn't, Clin Orthop, vol.455, pp.3-5, 1996.

N. N. Finer, W. A. Carlo, M. C. Walsh, W. Rich, and M. G. Gantz, Early CPAP versus surfactant in extremely preterm infants, N Engl J Med, vol.362, pp.1970-1979, 2010.

F. Sandri, R. Plavka, G. Ancora, U. Simeoni, Z. Stranak et al., Prophylactic or early selective surfactant combined with nCPAP in very preterm infants, Pediatrics, vol.125, pp.1402-1409, 2010.

K. J. Barrington, The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs, BMC Pediatr, vol.1, p.1, 2001.

P. Jarreau, M. Fayon, O. Baud, E. Autret-leca, M. Danan et al., Utilisation de la corticothérapie postnatale chez le nouveau-né prématuré dans la prévention et le traitement de la dysplasie bronchopulmonaire: état des lieux et conduite à tenir, Arch Pédiatrie, vol.17, pp.1480-1487, 2010.

C. Newborn, Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Pediatrics, vol.126, pp.800-808, 2010.

J. W. Kaempf, B. Campbell, R. S. Sklar, C. Arduza, R. Gallegos et al., Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams, Pediatrics, vol.111, pp.534-541, 2003.

S. C. Morton, M. R. Costlow, J. S. Graff, and R. W. Dubois, Standards and Guidelines for Observational Studies: Quality is in the Eye of the Beholder, J Clin Epidemiol, 2015.

L. W. Doyle, H. L. Halliday, R. A. Ehrenkranz, P. G. Davis, and J. C. Sinclair, An Update on the Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk of Bronchopulmonary Dysplasia, J Pediatr, vol.165, pp.1258-1260, 2014.